共 111 条
[1]
Eiger D(2020)The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC) Acta Oncol 59 723-725
[2]
Wagner M(2021)Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment Patient Prefer Adherence 15 611-623
[3]
Pondé NF(2013)Alopecia with endocrine therapies in patients with cancer Oncologist 18 1126-1134
[4]
Nogueira MS(2021)Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4/6 inhibitors: a systematic review Drug Saf 44 725-732
[5]
Beusterien K(2019)CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients J Clin Oncol 37 e 12537-35
[6]
Maculaitis MC(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-439
[7]
Hallissey B(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 17 425-2472
[8]
Saggar V(2018)Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 J Clin Oncol 36 2465-915
[9]
Wu S(2018)Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Lancet Oncol 19 904-2884
[10]
Dickler MN(2017)MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol 35 2875-3646